Evidence map›Paper›PMID 39844852›Full record

ArticleFrontiers in neuroscience2024

Mengjie He, Mengying Hu, Tingqiao Wang, Zeping Zuo, Hongkai Li, Zhiwei Zhao, Yunwen Hao, Xueling Dai, Jianfang Wang, Yaxuan Sun

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Molecular medicine reports · 2026
    Article
  3. Article
  4. Review
  5. Frontiers in endocrinology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengjie HeBeijing Key Laboratory of Bioactive Substances and Functional Food, Beijing Union University, Beijing, China.
Mengying HuSchool of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
Tingqiao WangBeijing Key Laboratory of Bioactive Substances and Functional Food, Beijing Union University, Beijing, China.
Zeping ZuoBeijing Tongrentang Company Limited, Beijing, China, China.
Hongkai LiBeijing Tongrentang Company Limited, Beijing, China, China.
Zhiwei ZhaoBeijing Tongrentang Company Limited, Beijing, China, China.
Yunwen HaoFaculty of Land and Food Systems, University of British Columbia, Vancouver, BC, Canada.
Xueling DaiBeijing Key Laboratory of Bioactive Substances and Functional Food, Beijing Union University, Beijing, China.
Jianfang Wang *Dongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Yaxuan Sun *Beijing Key Laboratory of Bioactive Substances and Functional Food, Beijing Union University, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, depression has become a global public health concern, and one of the common concomitant symptoms are diminished sexual motivation and impaired sexual performance. The aim of this study was to investigate the potential effects of Methods: Chronic unpredictable mild stress (CUMS)-induced depression model was constructed, and the effects of MOO on depression and sexual abilities were evaluated. Results: The results revealed that MOO was able to alleviate CUMS-induced depression-like behavior in mice, to inhibit hippocampal neuron apoptosis, to reverse monoamine neurotransmitter imbalance, increase Brain-derived neurotrophic factor (BDNF) expression levels in the hippocampus, to modulate the composition and distribution of gut microbiota, and to increase the abundance of probiotics after continuous gavage of MOO for 28 days. MOO further confirmed that sexual dysfunction is closely related to the development of depression by improving the lack of sexual motivation and low sexual performance in CUMS-induced depressed mice, modulating the disruption of sex hormone secretion in serum, and alleviating sperm morphology and functional defects in the epididymis. Conclusion: These findings on MOO provide a basis for exploring its antidepressant mechanism, its use to improve hypogonadotropic symptoms, and for future development of new antidepressant drug to improves hypogonadotropic symptoms.

Indexed as

BDNF/TrkB/CREB pathwayCUMSdepressiongut microbiotaMorinda officinalis oligosaccharidessexual dysfunction

Identifiers

PMID39844852
PMCPMC11750790

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.